Indication
Multiple Myeloma
Assets addressing this indication.
Total attributable cost
$13.7B
$67,608/patient
Drug spend
$6.7B
$33,012/patient
49% of total cost is drugs
All stages, prevalent population (2023 SEER estimate) · US
Indication
Assets addressing this indication.
Total attributable cost
$13.7B
$67,608/patient
Drug spend
$6.7B
$33,012/patient
49% of total cost is drugs
All stages, prevalent population (2023 SEER estimate) · US
168 of 168 assets